These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17072654)

  • 1. Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.
    Lauria A; Ippolito M; Almerico AM
    J Mol Model; 2007 Mar; 13(3):393-400. PubMed ID: 17072654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
    J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
    Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
    Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
    Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
    PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
    Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
    J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.
    Laco GS
    PLoS One; 2011; 6(8):e24314. PubMed ID: 21912628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.
    Marco E; Laine W; Tardy C; Lansiaux A; Iwao M; Ishibashi F; Bailly C; Gago F
    J Med Chem; 2005 Jun; 48(11):3796-807. PubMed ID: 15916431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.
    Laco GS; Du W; Kohlhagen G; Sayer JM; Jerina DM; Burke TG; Curran DP; Pommier Y
    Bioorg Med Chem; 2004 Oct; 12(19):5225-35. PubMed ID: 15351405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A theoretical study of some new analogues of the anti-cancer drug camptothecin.
    Jena NR; Mishra PC
    J Mol Model; 2007 Jan; 13(1):267-74. PubMed ID: 17024403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
    Pommier Y
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and properties of camptothecin derivatives, their protonated forms, and model interaction with the topoisomerase I-DNA complex.
    Ivanova B; Spiteller M
    Biopolymers; 2012 Feb; 97(2):134-44. PubMed ID: 21898362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
    Xiao X; Cushman M
    J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
    Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M
    Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity of DNA topoisomerases I and inhibitors.
    Pommier Y
    Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase I poisons and suppressors as anticancer drugs.
    Bailly C
    Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.
    Fan Y; Shi LM; Kohn KW; Pommier Y; Weinstein JN
    J Med Chem; 2001 Sep; 44(20):3254-63. PubMed ID: 11563924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin.
    Arimondo PB; Bailly C; Boutorine A; Sun JS; Garestier T; Hélène C
    C R Acad Sci III; 1999 Sep; 322(9):785-90. PubMed ID: 10547719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
    Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.